CDK1

NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression

Retrieved on: 
Monday, April 15, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CDK1, Phosphorylation, Safety, Cyclin-dependent kinase 2, Pharmacokinetics, Cell cycle, Patient, Endometrial cancer, Cyclin E, Standard of care, CDK2, Therapy, Cancer, Ovarian cancer, Pharmaceutical industry

NiKang Therapeutics Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.

Key Points: 
  • NiKang Therapeutics Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.
  • The Company announced today that the first patient has been dosed in a phase 1/1b, open-label, first-in-human dose escalation and expansion study of single agent NKT3447, a small molecule that inhibits cyclin-dependent kinase 2 (CDK2).
  • NKT3447 is designed to treat patients with cancers driven by cyclin E amplification or overexpression, which is present in many different tumor types.
  • The Phase 1/1b trial (NCT06264921) is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of NKT3447 in adult patients with advanced or metastatic solid tumors driven by cyclin E or CDK2.

NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Oncology, Health, Other Science, Clinical Trials, Research, Science, Biotechnology, CDK1, Phosphorylation, CDK2, CDK, Patient, Cell cycle, AACR, Therapy, Cancer, Safety, Pharmacokinetics, Cyclin E, Pharmaceutical industry

NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDKs, prolonged pharmacodynamic effects, and a distinct mechanism of action.

Key Points: 
  • NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDKs, prolonged pharmacodynamic effects, and a distinct mechanism of action.
  • It downregulates cyclin E and suppresses activating phosphorylation of CDK2 on Thr160.
  • “We are pleased to share the discovery of NKT3447, a highly selective CDK2 inhibitor with unique properties, at the AACR Annual Meeting”, said Zhenhai Gao, Ph.D., co-founder, president, and CEO of NiKang.
  • Discovery of a selective slow-off CDK2 inhibitor NKT3447 with distinct features of suppressing CDK2, downregulating cyclin E, and achieving prolonged pathway inhibition

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

Retrieved on: 
Thursday, January 4, 2024
Patient, CCNE1, Conference, AACR, CDK2, IND, Breast cancer, Drug development, SAN, Therapy, Cancer, CDK, CDK1, Toxicity, Pharmaceutical industry

SAN DIEGO, Calif. and NATICK, Mass., Jan. 4, 2024 /PRNewswire/ -- Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China). As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.

Key Points: 
  • (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China).
  • As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.
  • "With this agreement, we have laid the foundation for our potentially best-in-class oncology pipeline," said Athena Countouriotis, M.D., co-founder, president and CEO of Avenzo.
  • Allorion disclosed select data in poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023.

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

Retrieved on: 
Thursday, January 4, 2024
Patient, CCNE1, Conference, AACR, CDK2, IND, Breast cancer, Drug development, SAN, Therapy, Cancer, CDK, CDK1, Toxicity, Pharmaceutical industry

SAN DIEGO, Calif. and NATICK, Mass., Jan. 4, 2024 /PRNewswire/ -- Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China). As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.

Key Points: 
  • (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China).
  • As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.
  • "With this agreement, we have laid the foundation for our potentially best-in-class oncology pipeline," said Athena Countouriotis, M.D., co-founder, president and CEO of Avenzo.
  • Allorion disclosed select data in poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023.

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CCNE1, Conference, AACR, CDK2, IND, Breast cancer, Drug development, Therapy, Cancer, CDK, CDK1, Toxicity, Patient, Pharmaceutical industry

Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China).

Key Points: 
  • Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced that it has entered into an exclusive licensing agreement with Allorion Therapeutics Inc. (Allorion) to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China).
  • As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.
  • “With this agreement, we have laid the foundation for our potentially best-in-class oncology pipeline,” said Athena Countouriotis, M.D., co-founder, president and CEO of Avenzo.
  • Allorion disclosed select data in poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023.

CDK9 Inhibitor Pipeline Market Report 2022: Insights About 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022
Health, Pharmaceutical, Alvocidib, Merck & Co., Acute myeloid leukemia, III, CDK5, Cyclin T1, CTD, KDA, RNA polymerase II, Clinical trial, CDK, Discovery, Neoplasm, Cyclin-dependent kinase 9, Gene expression, ATP, II, Cancer, Cell cycle, Ligand Pharmaceuticals, SCH, Gene, Protein kinase, MYC, Pharmacopoeia, News, CDK2, Blockade, CDK9, Therapy, Association, Schering-Plough, RNA, Chronic lymphocytic leukemia, CDK1, Fertilizer, Vaccine, Pharmaceutical industry

This "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape.

Key Points: 
  • This "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape.
  • There are 2 isoforms of the CDK9 protein: the major 42 kDa CDK9 isoform, and the minor 55 kDa isoform.
  • 15+ key companies which are developing the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor.
  • The companies which have their Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drug candidates in the most advanced stage, i.e.

Cedilla Therapeutics Unveils Lead Programs for the Conditional Inhibition of TEAD and CDK2, Two High Value and Historically Undruggable Cancer Drivers

Retrieved on: 
Thursday, October 21, 2021
Biotechnology, Health, Science, Other Science, Oncology, TEAD, CDK1, Hippopotamus, Biotechnology, CDK2, LinkedIn, Cyclin E, Industry, Stomach, Mesothelioma, Squamous cell carcinoma, Patient, Esophageal cancer, Protein, Therapy, CDK, KRAS, Pharmaceutical industry

In addition, Cedilla is pursuing discovery research efforts against a portfolio of high value cancer targets.

Key Points: 
  • In addition, Cedilla is pursuing discovery research efforts against a portfolio of high value cancer targets.
  • Today, we are excited to announce our two lead programs from our internal efforts to discover conditional inhibitors: an inhibitor of TEAD and a highly selective inhibitor of CDK2.
  • We look forward to advancing these programs closer to the clinic and creating novel medicines with the potential to deliver profound benefit to patients.
  • The discovery of both programs was enabled by Cedillas novel approach to developing small molecule conditional inhibitors.